Compare NEXN & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEXN | DRUG |
|---|---|---|
| Founded | 2007 | 2019 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Pharmaceuticals and Biotechnology |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 367.2M | 364.8M |
| IPO Year | 2021 | N/A |
| Metric | NEXN | DRUG |
|---|---|---|
| Price | $6.66 | $84.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | $12.13 | ★ $83.00 |
| AVG Volume (30 Days) | ★ 361.0K | 156.6K |
| Earning Date | 11-13-2025 | 12-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 237.45 | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | ★ $376,353,000.00 | N/A |
| Revenue This Year | $5.43 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.51 | ★ N/A |
| Revenue Growth | ★ 7.80 | N/A |
| 52 Week Low | $6.08 | $23.18 |
| 52 Week High | $12.60 | $97.75 |
| Indicator | NEXN | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 45.03 | 59.78 |
| Support Level | $6.40 | $77.80 |
| Resistance Level | $6.95 | $97.75 |
| Average True Range (ATR) | 0.22 | 8.60 |
| MACD | 0.06 | -0.54 |
| Stochastic Oscillator | 38.81 | 48.89 |
Nexxen International Ltd is a globalized and flexible advertising technology platform with deep expertise in data and advanced TV that helps empower advertisers, agencies, digital publishers and broadcasters to achieve desired outcomes, including increased efficiency and returns, across the media supply chain. It is a demand-side platform (DSP), supply-side platform (SSP), ad server, and data management platform (DMP) and also delivers a flexible and unified technology stack with and exclusive data at its core. Company operates in America, APAC, EMEA, regions, with majority revenue from America.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.